Awareness of HBV Functional Cure and Attitude Toward Related Clinical Trials Among Patients with Chronic Hepatitis B in China

Hepatitis B Virus Knowledge and HBV-Related Surveillance Status Among HBsAg-Positive Patients in Qidong City: A Rural-Based Cross-Sectional Survey

OBJECTIVE

This study aimed to investigate hepatitis B knowledge and hepatitis B virus (HBV)-related surveillance status among HBsAg-positive patients, as well as to further explore the relevant influencing factors.

METHODS

A cross-sectional study was conducted on the HBsAg-positive patients from 8 October 2023 to 10 November 2023 in Qidong City. A self-report questionnaire was developed based on a literature review of similar studies. Univariate analysis of variance, multivariate logistic regression, and t-test analysis were conducted to analyze the collected data.

RESULTS

Of the 982 respondents who completed the on-site questionnaire, all participants were HBsAg-positive patients. Moreover, 51.32% had "good" knowledge of HBV. Multivariate logistic regression analysis showed that participants with a doctor in the family, those with an average monthly income above CNY 3000, and those with an average monthly income of CNY 1500-3000 were more likely to obtain a "good" cognitive evaluation (p < 0.001). The scores of the populations using HBV-related surveillance methods were low (2.02 ± 0.87); 64.87% (637/982) of the populations monitored had a score of no more than 2.

CONCLUSIONS

This study suggests that the awareness of HBV prevention and treatment among participants, especially those of low-income classes and individuals lacking physician clinical management, should be promoted to increase the dissemination of HBV knowledge.

Effect of interferon therapy on quality of life in patients with chronic hepatitis B

Interferon therapy is the most effective treatment for achieving clinical cure in chronic hepatitis B (CHB) patients. However, the treatment outcomes of interferon therapy are uncertain, multiple side effects can occur during treatment, and the treatment is expensive. Although these characteristics may affect patients' quality of life, research examining this topic is limited. We used a cross-sectional design to examine 100 CHB patients receiving interferon, 100 receiving nucleoside/nucleotide analogues, and 87 receiving non-antiviral treatment. Characteristic information, the Hepatitis B Quality of Life Instrument, Connor Davidson Resilience Scale, and Work Productivity and Activity Impairment Questionnaire were used to collect information. We found that quality of life in the interferon treatment group was higher than that in the non-antiviral treatment and nucleoside/nucleotide analogue treatment groups (p < 0.05). The factors influencing quality of life were resilience, presenteeism, hair loss, and antiviral treatment (p < 0.05). Although interferon therapy has some potential side effects, the results suggested that it did not negatively affect quality of life. Overall, interferon therapy did not have a major impact on CHB patients' daily lives and work.